ATE343592T1 - Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper - Google Patents

Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper

Info

Publication number
ATE343592T1
ATE343592T1 AT02774586T AT02774586T ATE343592T1 AT E343592 T1 ATE343592 T1 AT E343592T1 AT 02774586 T AT02774586 T AT 02774586T AT 02774586 T AT02774586 T AT 02774586T AT E343592 T1 ATE343592 T1 AT E343592T1
Authority
AT
Austria
Prior art keywords
igg1
hiv
epitope
antibodies
compositions
Prior art date
Application number
AT02774586T
Other languages
English (en)
Inventor
Gabriela Stiegler
Renate Kunert
Hermann Katinger
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of ATE343592T1 publication Critical patent/ATE343592T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02774586T 2001-09-07 2002-09-09 Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper ATE343592T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31809101P 2001-09-07 2001-09-07

Publications (1)

Publication Number Publication Date
ATE343592T1 true ATE343592T1 (de) 2006-11-15

Family

ID=23236607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774586T ATE343592T1 (de) 2001-09-07 2002-09-09 Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper

Country Status (8)

Country Link
US (1) US7595049B2 (de)
EP (1) EP1423417B1 (de)
JP (1) JP4243187B2 (de)
AT (1) ATE343592T1 (de)
AU (1) AU2002340880B2 (de)
DE (1) DE60215676T2 (de)
ES (1) ES2274100T3 (de)
WO (1) WO2003022879A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228939D0 (en) * 2002-12-12 2003-01-15 Univ Nottingham Peptide presentations for human immunodeficiency disease vaccines
EP1677825A4 (de) * 2003-09-19 2008-11-05 Scripps Research Inst An eine breit neutralisierende anti-hiv-antikörper-struktur des 4e10 fab fragmentkomplexes bindendes peptid, seine verwendungen und zusammensetzungen daraus
US8147840B2 (en) 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
CN1997751B (zh) * 2004-05-28 2012-08-29 艾更斯司股份有限公司 结合于psca蛋白的抗体以及相关分子
US8603736B2 (en) * 2004-06-07 2013-12-10 Monogram Biosciences, Inc. Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1877140A1 (de) * 2005-05-02 2008-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antikörper oder fragment davon mit neutralisierender wirkung gegen hiv
WO2008127651A1 (en) 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
EP4115900A1 (de) * 2021-07-05 2023-01-11 Diaccurate Neuartige antigene und impfstoffe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
AU693098B2 (en) * 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
EP1225907A4 (de) * 1999-10-05 2005-06-22 Epimmune Inc Induktion zellulärer immunantworten gegen humanes immundefiziens virus-1 (hiv-1) mittels peptid- und nukleinsäureverbindungen

Also Published As

Publication number Publication date
WO2003022879A3 (en) 2003-12-04
DE60215676D1 (de) 2006-12-07
AU2002340880B2 (en) 2007-08-23
WO2003022879B1 (en) 2003-12-31
JP4243187B2 (ja) 2009-03-25
US7595049B2 (en) 2009-09-29
EP1423417A2 (de) 2004-06-02
WO2003022879A2 (en) 2003-03-20
JP2005502708A (ja) 2005-01-27
DE60215676T2 (de) 2007-08-30
ES2274100T3 (es) 2007-05-16
EP1423417B1 (de) 2006-10-25
US20040241641A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
Broliden et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
Moore et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies
Zwick et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120
Jiang et al. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein
Fung et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
Profy et al. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual.
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
RU96102594A (ru) Тандемные синтетические hiv-1 пептиды
Choudhry et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DE60215676D1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
Molinos-Albert et al. Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals
Durda et al. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide
DE69332911D1 (de) Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus
Pinter Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
Zhou et al. Identification of a new epitope for HIV‐neutralizing antibodies in the gp41 membrane proximal external region by an Env‐tailored phage display library
Alsmadi et al. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
Hochleitner et al. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
Sabatier et al. Use of synthetic peptides for the detection of antibodies against the nef reguating protein in sera of HIV-infected patients
Hinz et al. Characterization of a trimeric MPER containing HIV-1 gp41 antigen
NZ515356A (en) Crystallised Fab'-epitope complex from the HIV-1 cross- neutralizing monoclonal antibody 2F5
WO2003059953B1 (en) Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
Laman et al. A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody
AU2002340880A1 (en) Peptides mimicking a cryptic epitope of GP41 HIV-1 and antibodies directed against them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423417

Country of ref document: EP